Skip to main content

Meet the SaaS Platform for Biopharma Manufacturing

Modicus Prime is building the first AI/ML real-time platform for quality control in biopharma manufacturing.

Research from Washington University and others estimates that $25-$50B is lost  annually due to destroyed biopharma products after manufacture. One prominent example is the 60 million doses of the J&J covid vaccine destroyed in 2021. Such losses are preventable, thanks to Modicus Prime’s technology, which detects  anomalies in real time. The company’s first AI -based product, mpVision, empowers manufacturers with no prior data science or AI experience to build complex ML models and run quality control in-line and in real time.

Deep founder expertise in pharmaceutical manufacturing

Founder Taylor Chartier earned a PhD in AI Biomedicine applications from the University of Luxembourg, one of the only schools globally to offer this particular PhD. Chartier spent time early in her career learning and developing a knowledge base at the intersection of process manufacturing and pharmaceuticals at firms like Merck and Emerald Therapeutics. She then transitioned to working as a senior process engineer at Bayer where she developed ML tools to enhance the commercial cell purification process. Ultimately through her experience of building an internal ML system to monitor quality control in real time at Bayer, Chartier saw the opportunity to build a company that could solve even more complex problems in the biopharma manufacturing.

Market validation for more accurate, more sustainable pharmaceutical manufacturing

Early pilots conducted by Modicus Prime demonstrated the startups ability to detect contaminated silicon oil particles with >99% accuracy in real-time, versus a post manufacturing discovery. This level of improved accuracy and efficiency could empowers pharma companies to get modern biologics to market safer and quicker, all while greatly reducing their waste output. On the heels of this huge win, Taylor and team converted this pilot to a commercial customer on a multi-year, multi-million dollar contract. General partner Gary Peat joins Modicus Prime’s board. His previous successful experience investing at seed includes leading half a dozen healthcare technology leaders to successful, life saving and financially rewarding outcomes, including Intouch’s $1.2B exit to Teladoc in 2020.

Hear Taylor talk more about Modicus Prime on the Tech AM podcast below.

 

Modicus Prime

Meet the SaaS Platform for Biopharma Manufacturing

Modicus Prime is building the first AI/ML real-time platform for quality control in biopharma manufacturing.

Research from Washington University and others estimates that $25-$50B is lost  annually due to destroyed biopharma products after manufacture. One prominent example is the 60 million doses of the J&J covid vaccine destroyed in 2021. Such losses are preventable, thanks to Modicus Prime's technology, which detects  anomalies in real time. The company's first AI -based product, mpVision, empowers manufacturers with no prior data science or AI experience to build complex ML models and run quality control in-line and in real time.

Deep founder expertise in pharmaceutical manufacturing

Founder Taylor Chartier earned a PhD in AI Biomedicine applications from the University of Luxembourg, one of the only schools globally to offer this particular PhD. Chartier spent time early in her career learning and developing a knowledge base at the intersection of process manufacturing and pharmaceuticals at firms like Merck and Emerald Therapeutics. She then transitioned to working as a senior process engineer at Bayer where she developed ML tools to enhance the commercial cell purification process. Ultimately through her experience of building an internal ML system to monitor quality control in real time at Bayer, Chartier saw the opportunity to build a company that could solve even more complex problems in the biopharma manufacturing.

Market validation for more accurate, more sustainable pharmaceutical manufacturing

Early pilots conducted by Modicus Prime demonstrated the startups ability to detect contaminated silicon oil particles with >99% accuracy in real-time, versus a post manufacturing discovery. This level of improved accuracy and efficiency could empowers pharma companies to get modern biologics to market safer and quicker, all while greatly reducing their waste output. On the heels of this huge win, Taylor and team converted this pilot to a commercial customer on a multi-year, multi-million dollar contract. General partner Gary Peat joins Modicus Prime's board. His previous successful experience investing at seed includes leading half a dozen healthcare technology leaders to successful, life saving and financially rewarding outcomes, including Intouch's $1.2B exit to Teladoc in 2020.

Hear Taylor talk more about Modicus Prime on the Tech AM podcast below.

 

Indianpolis, IN